Rosalía Riaza-Grau

A prognostic model for survival after salvage treatment with FLAG‐Ida +/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

M. Sanz, M. Barrios, J. Serrano, 2016, British journal of haematology.

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

E. Barragán, M. Sanz, M. Barrios, 2022, Disease markers.